RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Biology

Background:

• Mutant isocitrate dehydrogenases (IDHs) are common in acute myeloid leukemia (AML).
• Mutant IDHs produce R-2-hydroxyglutarate (R-2HG), which has shown inhibitory effects on AML cell growth.
• The precise mechanisms underlying R-2HG's anti-leukemia activity require further elucidation.

Purpose of the Study:

• To investigate the role of necroptosis in the anti-leukemia activity of R-2HG.
• To elucidate the molecular mechanisms by which R-2HG exerts its effects in AML cells.
• To identify potential therapeutic strategies for IDH-mutant AML.

Main Methods:

• In vitro studies using AML cell lines.
• Assays to measure enzyme activity (KDM2B), histone methylation, and protein expression (RIPK1, RIPK3).
• DNA methylation analysis and drug treatment (Decitabine).

Main Results:

• R-2HG inhibits lysine demethylase 2B (KDM2B), increasing histone 3 lysine 4 trimethylation.
• KDM2B inhibition promotes receptor-interacting protein kinase 1 (RIPK1) expression, inducing necroptosis in AML cells.
• IDH-mutant AML cells exhibit silenced RIPK3 expression due to DNA methylation, conferring resistance to R-2HG; Decitabine restores RIPK3 and R-2HG sensitivity.

Conclusions:

• R-2HG induces RIPK1-dependent necroptosis in AML cells through KDM2B inhibition.
• Loss of RIPK3 expression confers resistance to R-2HG-induced necroptosis in IDH-mutant AML.
• Restoring RIPK3 expression represents a potential therapeutic strategy to harness R-2HG's anti-leukemia effects in AML patients.